 Hesham Eissa
Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 15 | 2026 | 698 | 3.010 |
Why?
| | Severe Combined Immunodeficiency | 8 | 2026 | 22 | 2.810 |
Why?
| | Graft vs Host Disease | 7 | 2026 | 278 | 1.090 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2025 | 22 | 0.890 |
Why?
| | Cytomegalovirus | 1 | 2025 | 168 | 0.830 |
Why?
| | Transplantation Conditioning | 6 | 2026 | 191 | 0.810 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2026 | 65 | 0.580 |
Why?
| | Cancer Survivors | 5 | 2021 | 337 | 0.500 |
Why?
| | Mass Screening | 1 | 2025 | 1354 | 0.490 |
Why?
| | Positron-Emission Tomography | 2 | 2013 | 343 | 0.430 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 296 | 0.400 |
Why?
| | Burkitt Lymphoma | 1 | 2013 | 61 | 0.380 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2013 | 161 | 0.370 |
Why?
| | Lymphoma, B-Cell | 1 | 2013 | 137 | 0.360 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2010 | 3 | 0.330 |
Why?
| | Histocompatibility | 1 | 2010 | 20 | 0.330 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2010 | 35 | 0.320 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 120 | 0.310 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 297 | 0.290 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1146 | 0.270 |
Why?
| | Child | 14 | 2026 | 22670 | 0.260 |
Why?
| | Incidence | 2 | 2025 | 2915 | 0.260 |
Why?
| | Siblings | 2 | 2026 | 196 | 0.250 |
Why?
| | Cognition Disorders | 2 | 2022 | 539 | 0.250 |
Why?
| | Wiskott-Aldrich Syndrome | 1 | 2026 | 5 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 2 | 2013 | 2767 | 0.230 |
Why?
| | Child, Preschool | 8 | 2026 | 11835 | 0.230 |
Why?
| | Infant | 7 | 2026 | 10060 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1958 | 0.200 |
Why?
| | Neoplasms | 4 | 2021 | 2900 | 0.190 |
Why?
| | Agammaglobulinemia | 1 | 2022 | 36 | 0.180 |
Why?
| | Lymphopenia | 1 | 2022 | 62 | 0.180 |
Why?
| | Genetic Therapy | 1 | 2024 | 315 | 0.180 |
Why?
| | Humans | 26 | 2026 | 145140 | 0.180 |
Why?
| | Canada | 1 | 2023 | 429 | 0.180 |
Why?
| | Prognosis | 2 | 2025 | 4310 | 0.170 |
Why?
| | Retrospective Studies | 7 | 2026 | 17247 | 0.170 |
Why?
| | Remission Induction | 2 | 2013 | 306 | 0.170 |
Why?
| | Radiation Dosage | 2 | 2013 | 193 | 0.170 |
Why?
| | Infant, Newborn | 5 | 2024 | 6435 | 0.170 |
Why?
| | Infertility | 1 | 2021 | 61 | 0.170 |
Why?
| | Immune Reconstitution | 1 | 2021 | 10 | 0.170 |
Why?
| | Hypogonadism | 1 | 2021 | 92 | 0.170 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5411 | 0.170 |
Why?
| | Pleural Effusion | 1 | 2021 | 59 | 0.160 |
Why?
| | Testicular Neoplasms | 1 | 2021 | 111 | 0.160 |
Why?
| | Endocrine System Diseases | 1 | 2019 | 35 | 0.150 |
Why?
| | Genotype | 1 | 2024 | 1844 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2021 | 172 | 0.150 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 23 | 0.150 |
Why?
| | Adolescent | 8 | 2026 | 22479 | 0.140 |
Why?
| | Prevalence | 1 | 2025 | 2855 | 0.140 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 168 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.130 |
Why?
| | Male | 12 | 2026 | 72664 | 0.130 |
Why?
| | Transplantation, Homologous | 2 | 2026 | 417 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2026 | 11741 | 0.120 |
Why?
| | Vaccines | 1 | 2021 | 388 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 497 | 0.110 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 478 | 0.110 |
Why?
| | Female | 10 | 2026 | 78636 | 0.110 |
Why?
| | Cost of Illness | 1 | 2017 | 324 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 686 | 0.110 |
Why?
| | Quality of Life | 3 | 2022 | 3194 | 0.100 |
Why?
| | Radiopharmaceuticals | 1 | 2013 | 205 | 0.090 |
Why?
| | Chemoradiotherapy | 1 | 2013 | 239 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 2207 | 0.090 |
Why?
| | Karyotyping | 1 | 2010 | 105 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1993 | 0.080 |
Why?
| | Histocompatibility Testing | 1 | 2010 | 123 | 0.080 |
Why?
| | Bone Marrow | 2 | 2022 | 306 | 0.080 |
Why?
| | Hodgkin Disease | 1 | 2012 | 171 | 0.080 |
Why?
| | Longitudinal Studies | 2 | 2023 | 2949 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1467 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2022 | 673 | 0.070 |
Why?
| | Disease-Free Survival | 1 | 2010 | 766 | 0.070 |
Why?
| | Body Mass Index | 1 | 2017 | 2437 | 0.070 |
Why?
| | Heart Failure | 1 | 2021 | 2324 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 4071 | 0.070 |
Why?
| | Age Factors | 2 | 2017 | 3338 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2183 | 0.060 |
Why?
| | Recurrence | 1 | 2010 | 1134 | 0.060 |
Why?
| | Cohort Studies | 2 | 2016 | 5988 | 0.060 |
Why?
| | Cross-Sectional Studies | 2 | 2020 | 5886 | 0.060 |
Why?
| | Monitoring, Immunologic | 1 | 2026 | 24 | 0.060 |
Why?
| | Adult | 7 | 2026 | 40665 | 0.060 |
Why?
| | Risk Factors | 3 | 2020 | 10857 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1657 | 0.060 |
Why?
| | Phenotype | 2 | 2026 | 3138 | 0.050 |
Why?
| | Young Adult | 4 | 2026 | 14176 | 0.050 |
Why?
| | Disease Progression | 2 | 2022 | 2857 | 0.050 |
Why?
| | Tissue Donors | 1 | 2026 | 419 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2928 | 0.050 |
Why?
| | Adenosine Deaminase | 1 | 2022 | 43 | 0.040 |
Why?
| | Thymus Gland | 1 | 2022 | 311 | 0.040 |
Why?
| | Neonatal Screening | 1 | 2023 | 179 | 0.040 |
Why?
| | Immunologic Tests | 1 | 2021 | 16 | 0.040 |
Why?
| | Blood Cell Count | 1 | 2021 | 55 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2022 | 180 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2021 | 167 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2023 | 1325 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 52 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2019 | 95 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 199 | 0.040 |
Why?
| | Spleen | 1 | 2021 | 507 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2022 | 522 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2019 | 318 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2019 | 440 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2022 | 1134 | 0.030 |
Why?
| | Middle Aged | 3 | 2020 | 36126 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 206 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 917 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2022 | 1138 | 0.030 |
Why?
| | Radiotherapy | 1 | 2016 | 204 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 834 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2087 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1371 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1806 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1597 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 932 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3616 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2504 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 8035 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6055 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7107 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5208 | 0.010 |
Why?
| | Aged | 1 | 2020 | 26096 | 0.010 |
Why?
|
|
Eissa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|